Two Diagnoses at Once
When a family finds out their herding breed has cancer, they already have more to process than any person should. The prognosis conversations. The treatment decision tree. The financial reality. The grief that begins before you’ve even finished grieving.
And then, for families who know about MDR1, there’s a second layer: which treatments are safe? Does the MDR1 mutation interact with chemotherapy? What about the pain medications your dog will need during treatment? Does the mutation change everything, or just some things?
I’ve been contacted by families in exactly this situation, trying to navigate an oncology referral while simultaneously worrying about whether the treatments will help their dog or hurt them in a different way. This article is for them, and for anyone who might find themselves in this position in the future.
MDR1 and Cancer: The Complicated Connection
The MDR1 gene - more precisely called ABCB1 - was originally named for its role in multi-drug resistance. Not in dogs, but in cancer. In human oncology research, the P-glycoprotein pump was first identified because cancer cells sometimes overexpressed it, pumping out chemotherapy drugs and making tumors resistant to treatment.
This means the relationship between the ABCB1 gene and cancer drugs is not straightforward.
For dogs with the MDR1 mutation, the absence of P-glycoprotein function can actually mean that some chemotherapy drugs penetrate more effectively - potentially increasing both efficacy and toxicity. For other drugs, the relationship is more complicated or not clinically significant.
This is why MDR1 status needs to be part of the conversation with any veterinary oncologist treating a herding breed. Not because treatment is impossible, but because dosing protocols may need adjustment, and monitoring may need to be more intensive.
Chemotherapy Drugs and MDR1 Status
Vincristine
Vincristine is a commonly used chemotherapy agent in canine lymphoma protocols. It is a P-glycoprotein substrate. Mutant/mutant dogs may have higher plasma concentrations of vincristine than normal dogs at the same dose, and some veterinary oncologists recommend dose reduction and increased monitoring in MDR1-affected dogs.
Doxorubicin
Doxorubicin (Adriamycin) is another foundational cancer drug in veterinary oncology and is a P-glycoprotein substrate. Similar considerations apply. Your oncologist should be aware of your dog’s MDR1 status before designing a doxorubicin-containing protocol.
Cyclophosphamide
Cyclophosphamide is generally not considered a significant P-glycoprotein substrate, and MDR1 status is not thought to substantially alter its pharmacokinetics.
Lomustine (CCNU)
Used in some lymphoma and mast cell tumor protocols. Some evidence suggests P-glycoprotein interaction. Monitoring complete blood counts closely is standard practice with lomustine regardless of MDR1 status; this monitoring should be especially rigorous in MDR1-affected dogs.
Prednisone and Prednisolone
Corticosteroids are used extensively in cancer treatment and are safe in MDR1-affected dogs at appropriate doses. No special modification is required based on MDR1 status.
Pain Management During Cancer Treatment
This is where many families get caught off-guard. They focus on the chemotherapy drugs, then encounter a pain management prescription that raises MDR1 concerns.
Tramadol
Tramadol is widely used for cancer pain in dogs and is generally considered safe for MDR1-affected dogs. It is not a significant P-glycoprotein substrate at typical doses.
Gabapentin
Also commonly used for cancer-related pain and neuropathy. Not a P-glycoprotein substrate. Safe for MDR1-affected dogs.
Buprenorphine
A partial opioid agonist used for moderate pain. Not considered a significant P-glycoprotein substrate at clinical doses.
NSAIDs (Rimadyl, Meloxicam, Galliprant)
Non-steroidal anti-inflammatory drugs are not P-glycoprotein substrates. Standard use is appropriate in MDR1-affected dogs.
Butorphanol
Used for moderate pain and as a pre-anesthetic. Some evidence of enhanced effects in MDR1-affected dogs at higher doses. Dose reduction may be appropriate.
Hydromorphone and Morphine
Opioids used for more severe pain. Some evidence of altered pharmacokinetics in MDR1-affected dogs. Worth discussing with the treating veterinarian.
Anti-Nausea Medications During Chemotherapy
Chemotherapy often requires anti-emetic (anti-nausea) medications. Good news here: the most commonly used veterinary anti-emetics (ondansetron, maropitant/Cerenia, metoclopramide) are not significant P-glycoprotein substrates and are considered safe for MDR1-affected dogs.
Cerenia in particular is widely used in veterinary oncology and has a well-established safety profile in herding breeds.
Working With a Veterinary Oncologist
If your dog is facing cancer, you should be working with a board-certified veterinary oncologist, not just your general practitioner. This is true for all dogs with cancer, but especially for MDR1-affected dogs where treatment protocols require specialized pharmacological knowledge.
When you make that appointment:
Before the first oncology visit:
- Bring your dog’s MDR1 test results. If you don’t have them, our MDR1 testing guide explains how to get tested quickly.
- Request that MDR1 status be part of the initial consultation
- Ask specifically about dose modification for any P-glycoprotein-substrate drugs in the proposed protocol
Questions to ask the oncologist:
- Which drugs in this protocol are P-glycoprotein substrates?
- How does my dog’s MDR1 status affect dosing decisions?
- What monitoring will you do to check for drug accumulation?
- Are there alternative protocol options if my dog is mutant/mutant?
Most veterinary oncologists at academic medical centers and specialty practices will be familiar with MDR1. If yours isn’t, or seems dismissive, that is important information. You can ask for a second opinion or request a consultation with a veterinary clinical pharmacologist.
The Emotional Weight of This
I want to acknowledge something that the clinical information above doesn’t cover.
Navigating a cancer diagnosis is already one of the hardest things a pet owner can do. Adding MDR1 complexity on top of that - worrying about whether the treatment itself might hurt your dog, trying to understand P-glycoprotein substrates while you’re barely holding yourself together - is genuinely overwhelming.
If you’re in this situation, please reach out. Our support and community resources include connections to other families who have navigated cancer treatment in MDR1-affected dogs. You don’t have to figure this out alone. There are people who have been exactly where you are and who can help you ask the right questions, advocate in the exam room, and carry some of the weight when it feels like too much.
Prevention Still Matters, Even Here
One thing I want to say clearly: knowing about MDR1 doesn’t prevent cancer. But knowing your dog’s MDR1 status, having that information in their file, being prepared to have this conversation with an oncologist - all of that can make a meaningful difference in treatment outcomes if cancer does come.
Every herding breed should be tested. The vet visit checklist we’ve developed includes prompts for all major health decisions, including how to communicate MDR1 status in oncology settings.
Cancer is terrible. MDR1-related drug reactions are preventable. You can’t always prevent the first thing, but you can absolutely prevent the second. That’s worth something. It’s worth the $75 test, the conversation at every vet visit, the printout in your car.
Do it now, before you need it in the most stressful circumstances imaginable.
This article reflects available scientific literature and the experiences of our community. It is not a substitute for care by a board-certified veterinary oncologist. Treatment decisions for canine cancer require individualized medical assessment. If you have questions or experiences to share, please contact us.